Anavex Life Sciences Corp (AVXL)

[bas2020]

1) ADAS-Cog and CDR-SB (p < .025), proving further evidence of stat. sig. improvements and trial success, was for combined treatment arms. Therefore, your dose-level concern is irrelevant to this measure.
2) Missling stated mid last year that they felt it worthwhile to wait for the Excellence results, before preceding further with AD, in order to secure the voucher. Now that the Excellence results are in, we're seeing Anavex moving forward with AD... with the EMA and soon with the FDA.

Anavex is more concerned with impressing RAs with the full data, than a few worrisome shareholders.
Expect to see the full P2b/3 data in the upcoming peer-reviewed article.